May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 20, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 11, 2020
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Sep 11, 2019
The global Tourette's syndrome drugs market at a CAGR of almost 5% during the forecast period
Jul 15, 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Jan 06, 2019
Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Nov 29, 2018
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Aug 29, 2018
Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Jul 02, 2018
FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia
May 23, 2018
Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
May 03, 2018
Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program
Apr 30, 2018
Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting
Apr 26, 2018
Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia
Nov 10, 2017
Rising Competition for Treating Positive Symptoms of Schizophrenia Requires Companies to Focus on Therapies for Negative and Cognitive Symptoms